Hemophilia Drugs Market to Grow at 4.76% CAGR to 2020

PUNE, India, November 2, 2016 /PRNewswire/ --

2016 hemophilia drugs market research says one trend gaining traction in this market is increase in technological innovations. Currently, most of the hemophilia therapeutics available in the market are short-acting i.e., used only for when the individual suffers from bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products.

Complete report on hemophilia drugs market spread across 84 pages, analyzing 5 major companies and providing 61 data exhibits is now available at http://www.rnrmarketresearch.com/global-hemophilia-drugs-market-2016-2020-market-report.html.

The analysts forecast global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020. According to the hemophilia drugs market report, drugs with prolonged action will drive the market. Earlier, parenteral formulations for treating hemophilia B required frequent administration of replacement factors. Drugs with favorable pharmacokinetic profiles, including prolonged mechanism of action are fast gaining acceptance among physicians and individuals. These long-acting formulations reduce the need for repeated dosing of medications, reducing injection site pain.

According to the industry research analysts, the recombinant therapies segment accounted for the most of the hemophilia drugs market revenue shares and will continue to lead the market over the coming years. The growth of this segment is attributed to the increasing demand for prophylaxis therapies in developed countries and shift in preference from plasma-derived therapies to recombinant products in the emerging economies. Moreover, the entry of long-acting recombinant products such as ALPROLIX by Biogen, Advate by Baxter, among others will contribute to this segment's growth over the coming years.

Americas led the global hemophilia drugs market in 2015 and is expected to continue its dominance until the end of 2020. The Americas have the highest revenue share in the global hemophilia drugs market with the US contributing to the majority of this revenue. Several countries in the region have introduced health care reforms which are having a positive impact on the market growth. Moreover, healthcare reforms in the US have also helped reduce the cost of pharmaceutical drugs, increased access to healthcare, and improved the overall quality of healthcare. These healthcare reforms are likely to have a positive impact on healthcare insurance and also reduce hospital stay and overall medical expenses which will boost hemophilia drugs market growth in the region.

The following companies are the key players in the global hemophilia drugs market: Baxalta, Bayer, CSL Behring, Novo Nordisk, and Pfizer. Other prominent vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, and UniQure Biopharma. Order a copy of Global Hemophilia Drugs Market 2016-2020 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=733369.

Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

Another related report is Global Alpha-1 Antitrypsin Drugs Market 2016-2020, a key driver is the improved diagnosis of AATD. AATD is difficult to diagnose in the majority of cases. The Alpha-1 Foundation reports that around 3% of all people who have diagnosed with COPD may have undetected AATD. The condition is misdiagnosed in most of the cases as asthma, smoking-related COPD, bronchitis, bronchiectasis, or other pulmonary conditions. These underlying conditions may confuse the clinical picture and thus lead to the difficulty in diagnosis. However, awareness programs conducted by various organizations worldwide will help in recognizing and differentiating the condition from other diseases. Browse complete report @ http://www.rnrmarketresearch.com/global-alpha-1-antitrypsin-drugs-market-2016-2020-market-report.html.

Explore other new reports on Diseases & Treatment Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment.

About Us: 

RnRMarketResearch.com is your single source for all market research needs. Our database includes 100,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. We provide 24/7 online and offline support to our customers.

Contact:  
Ritesh Tiwari
2nd floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune-411001
Maharashtra, India
+1 888 391 5441
sales@rnrmarketresearch.com